| Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group M Lobera, KP Madauss, DT Pohlhaus, QG Wright, M Trocha, DR Schmidt, ... Nature chemical biology 9 (5), 319-325, 2013 | 371 | 2013 |
| Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship IM Shapiro, VN Kolev, CM Vidal, Y Kadariya, JE Ring, Q Wright, ... Science translational medicine 6 (237), 237ra68-237ra68, 2014 | 249 | 2014 |
| PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells VN Kolev, QG Wright, CM Vidal, JE Ring, IM Shapiro, J Ricono, ... Cancer research 75 (2), 446-455, 2015 | 138 | 2015 |
| Role of microbiota in strengthening ocular mucosal barrier function through secretory IgA A Kugadas, Q Wright, J Geddes-McAlister, M Gadjeva Investigative ophthalmology & visual science 58 (11), 4593-4600, 2017 | 93 | 2017 |
| Inhibition of FAK kinase activity preferentially targets cancer stem cells VN Kolev, WF Tam, QG Wright, SP McDermott, CM Vidal, IM Shapiro, ... Oncotarget 8 (31), 51733, 2017 | 81 | 2017 |
| Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner L Cushing, W Stochaj, M Siegel, R Czerwinski, K Dower, Q Wright, ... Journal of Biological Chemistry 289 (15), 10865-10875, 2014 | 62 | 2014 |
| Evolution of cancer vaccines—Challenges, achievements, and future directions BQ Tay, Q Wright, R Ladwa, C Perry, G Leggatt, F Simpson, JW Wells, ... Vaccines 9 (5), 535, 2021 | 57 | 2021 |
| PD-1 and beyond to activate T cells in cutaneous squamous cell cancers: the case for 4-1BB and VISTA antibodies in combination therapy Q Wright, JL Gonzalez Cruz, JW Wells, GR Leggatt Cancers 13 (13), 3310, 2021 | 7 | 2021 |
| Liposomal Formulations of a Polyleucine–Antigen Conjugate as Therapeutic Vaccines against Cervical Cancer FZ Firdaus, S Bartlett, WM Hussein, L Lu, Q Wright, W Huang, UJ Nahar, ... Pharmaceutics 15 (2), 602, 2023 | 6 | 2023 |
| Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014; 6 (237): 237ra68 IM Shapiro, VN Kolev, CM Vidal, Y Kadariya, JE Ring, Q Wright, ... Epub 2014/05/23, 0 | 6 | |
| Abstract A39: FAK inhibitors VS-6063 and VS-4718 preferentially target ovarian cancer stem cells VN Kolev, QG Wright, CM Vidal, WF Tam, MV Pavdal, Q Xu, JA Pachter Clinical Cancer Research 19 (19_Supplement), A39-A39, 2013 | 4 | 2013 |
| Focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718 target cancer stem cells. Q Xu, VN Kolev, QG Wright, IM Shapiro, CM Vidal, M Padval, M Keegan, ... Journal of Clinical Oncology 31 (15_suppl), e13523-e13523, 2013 | 4 | 2013 |
| Repurposing of commercially existing molecular target therapies to boost the clinical efficacy of immune checkpoint blockade D Sinha, P Moseley, X Lu, Q Wright, B Gabrielli, IH Frazer, JLG Cruz Cancers 14 (24), 6150, 2022 | 3 | 2022 |
| Abstract C262: Malignant mesothelioma lacking merlin shows enhanced sensitivity to the FAK inhibitor defactinib (VS-6063): Elucidation of the merlin-FAK relationship. IM Shapiro, VN Kolev, Y Kadariya, CM Vidal, QG Wright, JE Ring, ... Molecular Cancer Therapeutics 12 (11_Supplement), C262-C262, 2013 | 3 | 2013 |
| Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells. CM Vidal, VN Kolev, QG Wright, WF Tam, DT Weaver, MV Padval, Q Xu, ... Molecular Cancer Therapeutics 12 (11_Supplement), C271-C271, 2013 | 3 | 2013 |
| Abstract B283: Defactinib (VS-6063) targets cancer stem cells directly and through inhibition of tumor-associated macrophages and cytokine production. JE Ring, VN Kolev, IM Shapiro, QG Wright, JR Testa, MV Padval, Q Xu, ... Molecular Cancer Therapeutics 12 (11_Supplement), B283-B283, 2013 | 3 | 2013 |
| Role of Microbiota in Strengthening Ocular Mucosal Barrier Function Through Secretory IgA QG Wright | 1 | 2017 |
| VS‐5584 a dual mTORC1/2 and PI3K inhibitor has anti-tumor activity in multiple in vivo xenograft tumor models and enhanced efficacy in combination with cisplatin … AF Trombino, VN Kolev, QG Wright, Q Xu, MV Padval Cancer Research 74 (19_Supplement), 213-213, 2014 | 1 | 2014 |
| Abstract P2-09-14: Focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718 target breast cancer stem cells JA Pachter, VN Kolev, QG Wright, CM Vidal, MV Pavdal, JE Ring, ... Cancer Research 73 (24_Supplement), P2-09-14-P2-09-14, 2013 | 1 | 2013 |
| 405 the pan-PI3K/mTORKinase inhibitor VS-5584 preferentially targets cancer stem cells in breast cancer models JA Pachter, VN Kolev, AA Neill, QG Wright, MV Padval, Q Xu European Journal of Cancer, 123, 2012 | 1 | 2012 |
Jazmina Libertad Gonzalez CruzGroup leader of the Cancer Immunology and Therapy group, The University of Queensland在 uq.edu.au 的电子邮件经过验证
